预测的HLA T细胞表位靶点与肾移植后T细胞介导排斥反应的关联
该回顾性队列研究纳入单中心2004至2013年间893例有活检数据和高分辨率HLA配型的肾移植受者,评估供者HLA来源的T细胞表位靶点(PIRCHE-II评分和HLA eplet错配)与T细胞介导排斥反应(TCMR)及移植物失败的关系。多变量分析显示,仅HLA-DRB1和HLA-DQB1的PIRCHE-II评分独立与TCMR及移植物失败相关,而HLA I类分子无此关联。
要点
- 在无HLA-DSA情况下,HLA II类而非I类错配与早期急性TCMR及移植物失败相关。
- 仅HLA-DRB1和HLA-DQB1的PIRCHE-II评分独立与TCMR和移植物失败相关。
- TCMR患者HLA II类PIRCHE-II评分中位数与无TCMR患者存在统计学差异。
核心结论
- 在缺乏HLA-DSA的情况下,HLA II类而非I类错配与早期急性TCMR发作及移植物失败相关。
- 作者认为当前免疫抑制治疗大体能阻断最具破坏性的HLA I类导向的同种免疫过程,但针对HLA-DRB1和HLA-DQB1分子错配的同种反应仍未被充分抑制。
研究设计与样本
- 回顾性队列研究,纳入单中心2004至2013年间所有具有活检数据和用于高分辨率HLA供受者配型的DNA样本的肾移植受者(N=893)。
- 暴露为通过HLA匹配算法PIRCHE-II和HLA eplet错配计算的评分。
- 结局为TCMR、提示TCMR的交界性改变及移植物失败。
- 采用多变量病因特异性风险模型分析HLA表位靶点与研究结局的关联。
主要发现
- 277例患者发生TCMR,134例仅至少1次活检显示提示TCMR的交界性改变。
- 多变量分析中,仅HLA-DRB1和HLA-DQB1的PIRCHE-II评分独立与TCMR发生及移植物失败相关;HLA I类分子无此关联。
- 若限定为移植后前3个月内的排斥发作,仅源自供者HLA-DRB1和HLA-DQB1的T细胞表位靶点与早期急性TCMR相关,而I类分子不相关。
- TCMR患者与无TCMR患者的HLA II类PIRCHE-II评分中位数存在统计学差异(129 [IQR, 60-240] vs 201 [IQR, 96-298],P < 0.0001)。
- HLA I类PIRCHE-II评分未观察到上述差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 观察性临床数据及残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The relationship between human leukocyte antigen (HLA) molecular mismatches and T-cell-mediated rejection (TCMR) is unknown. We investigated the associations between the different donor HLA-derived T-cell targets and the occurrence of TCMR and borderline histologic changes suggestive of TCMR after kidney transplantation. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: All kidney transplant recipients at a single center between 2004 and 2013 with available biopsy data and a DNA sample for high-resolution HLA donor/recipient typing (N = 893). EXPOSURE: Scores calculated by the HLA matching algorithm PIRCHE-II and HLA eplet mismatches. OUTCOME: TCMR, borderline changes suggestive of TCMR, and allograft failure. ANALYTICAL APPROACH: Multivariable cause-specific hazards models were fit to characterize the association between HLA epitopes targets and study outcomes. RESULTS: We found 277 patients developed TCMR, and 134 developed only borderline changes suggestive of TCMR on at least 1 biopsy. In multivariable analyses, only the PIRCHE-II scores for HLA-DRB1 and HLA-DQB1 were independently associated with the occurrence of TCMR and with allograft failure; this was not the case for HLA class I molecules. If restricted to rejection episodes within the first 3 months after transplantation, only the T-cell epitope targets originating from the donor's HLA-DRB1 and HLA-DQB1, but not class I molecules, were associated with the early acute TCMR. Also, the median PIRCHE-II score for HLA class II was statistically different between the patients with TCMR compared to the patients without TCMR (129 [IQR, 60-240] vs 201 [IQR, 96-298], respectively; P < 0.0001). These differences were not observed for class I PIRCHE-II scores. LIMITATIONS: Observational clinical data and residual confounding. CONCLUSIONS: In the absence of HLA-DSA, HLA class II but not class I mismatches are associated with early episodes of acute TCMR and allograft failure. This suggests that current immunosuppressive therapies are largely able to abort the most deleterious HLA class I-directed alloimmune processes; however, alloresponses against HLA-DRB1 and HLA-DQB1 molecular mismatches remain insufficiently suppressed. PLAIN-LANGUAGE SUMMARY: Genetic differences in the human leukocyte antigen (HLA) complex between kidney transplant donors and recipients play a central role in T-cell-mediated rejection (TCMR), which can lead to failure of the transplanted kidney. Evaluating this genetic disparity (mismatch) in the HLA complex at the molecular (epitope) level could contribute to better prediction of the immune response to the donor organ posttransplantation. We investigated the associations of the different donor HLA-derived T-cell epitope targets and scores obtained from virtual crossmatch algorithms with the occurrence of TCMR, borderline TCMR, and graft failure after kidney transplantation after taking into account the influence of donor-specific anti-HLA antibodies. This study illustrates the greater importance of the molecular mismatches in class II molecules compared to class I HLA molecules.
引用
- Senev A, Van Loon E, Lerut E, et al. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation. Am J Kidney Dis. 2022. PMID: 35690154. doi:10.1053/j.ajkd.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。